Assessment of Drugs’ Donation Practices in Sudan

Jacob L. Doro, Asim F Mustafa, Ahmed S. Eldalo, Mirghani A. Yousif

.

DOI: 10.4236/pp.2012.31017                

Abstract

The quality requirements of drug donation are different from those of other donated items. Purpose: To describe and assess key aspects of pharmaceutical donations in Sudan, the kinds of benefits and drawbacks associated with drug donations, and the government controlling role in the donation process. Methods: Retrospective and prospective studies were conducted in the period from April 2007 to Mar 2008 in the Federal Ministry of Health (FMOH) and some working NGOs’ data bases. Some quality aspects of donated drugs were explored. Six randomly selected nongovernmental organizations (NGOs) were examined for the relevance and some aspects of quality of donated drugs such as whether the donated drugs were listed in the National Essential Drug List, or labeled in International Nonproprietary Names, their dosage forms, the language on the package and if the donated drugs were sampled or returned ones. Results: The study showed that most of the donated drugs were relevant to NEDL normative standards. The median times from the date of arrival to the date of expiration were more than 400 days. The time prior to expiration range between 44.8% and 47.5% were found less than one year in arrival. The top ten therapies were accounted for about 40 shipped items. The study was revealed that Sudan did not develop its own guidelines for drug donations and NGOs are making no effort to develop written donation policies. Conclusion: development of national guidelines for drug donations is essential to control the donated drugs in Sudan.

Keywords

Assessment; Drug Donation; Practices; Sudan

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	H. V. Hogerzeil, M. R. Couper and R. Gray, “Guidelines for Drug Donations,” British Medical Journal (BMJ), Vol. 314, 1997, p. 737. doi: 10.1136/bmj.314.7082.737
[2]	“Australian Guidelines for Drug Donations to Developing Countries,” Amendments Endorsed, November 2000
[3]	“Guidelines for Drug Donations,” WHO/EDM/PAR/99.4 Revised, 1999.
[4]	E. Hoen and C. Hodgkin, “Harmful Use of Donated Veterinary Drug,” Lancet, Vol. 2, 1993, pp. 308-209. doi: 10.1016/0140-6736(93)91856-H
[5]	B. Snell, “Inappropriate Drug Donations: The Need for Reform,” Lancet, Vol. 758, 2001, p. 9281.
[6]	M. R. Riech, “Pharmaceutical Donations: Players, Processes, and Products, “Assessment of US Pharmaceutical Donations, 1999.
[7]	Pharmacien Sans Fronteire Comite International, “Accessibility for Everyone to Quality Pharmaceutical Care,” Press Release, 2004.
[8]	Srilanka Ministry of Health, “Most Tsunami Drug Donations Were Useless and Dangerous (Report),” The Sunday times online, Vol. 41, No. 34, 2007, pp. 1391-0531.
[9]	World Health Organization, “Think before You Send,” WHO Regional Office for Europe, Press Release, Zagreb, 1999.
[10]	WHO/EDM/PAR. (1998) “Guidelines for Safe Disposal of Unwanted Pharmaceuticals in and after Emergencies,” Geneva: World Health Organization. WHO/EDM/PAR/ 98.2
[11]	M. Bonati, “Drug Donations to Bosnia-Herzegovina Are Often Inappropriate,” British Medical Journal (BMJ), Vol. 313, 1996, pp. 87-90. doi:10.1136/bmj.313.7063.1011b
[12]	J. A. Patricia and M. R. Riech, “PVO Pharmaceutical Donations: Making the Incentive Fit the Need,” Journal of Research in Pharmaceutical Economics, Vol. 804, 1990, pp. 40-60.